Clinical Trials Browser

Phase 2 × Has results × Acetaminophen × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT01391962 2026-02-02

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Phase 2 Completed

34 enrolled 22 charts

Sarcoma

Sarcoma, Alveolar Soft Part

NCT00712712 2025-08-29

MEDOR

Phase 2 Completed

78 enrolled 28 charts

Neoplasm Metastasis, Pain

NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Phase 2 Active not recruiting

69 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

NCT03084536 2024-12-24

PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery

Phase 2 Completed

134 enrolled 9 charts

Breast

Breast Neoplasms

NCT04660799 2023-10-12

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Completed

50 enrolled 25 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02999633 2022-03-21

ISLAY

Phase 2 Terminated

14 enrolled 7 charts

LymphoidOther hematologic neoplasm

Leukemia, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00185692 2019-12-04

Allogeneic Transplantation From Related Haploidentical Donors

Phase 2 Completed

16 enrolled 8 charts

LymphoidOther hematologic neoplasm

Graft vs Host Disease, Hodgkin Disease, Leukemia, Neoplasms, Hematologic Neoplasms

NCT01985126 2018-06-25

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Phase 2 Completed

124 enrolled 18 charts

Plasma cell

Multiple Myeloma

NCT00482053 2018-05-14

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Phase 2 Terminated

3 enrolled 13 charts

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00186628 2017-11-28

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Phase 2 Completed

36 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Mast-Cell, Lymphoma, Mantle-Cell

NCT00899847 2017-10-20

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Phase 2 Completed

9 enrolled 15 charts

Plasma cell

Multiple Myeloma

NCT00490009 2017-03-30

Phase 2 Study of Bexxar in Relapsed/Refractory DLCL

Phase 2 Completed

9 enrolled 10 charts

Lymphoid

Lymphoma

Clinical Trials

MK-3475-01C

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

MEDOR

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

ISLAY

Allogeneic Transplantation From Related Haploidentical Donors

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Phase 2 Study of Bexxar in Relapsed/Refractory DLCL